Enrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept's CNSide(TM) Assay to Evaluate Patients with Leptomeningeal Metastases
Stock Information for Biocept Inc.
Loading
Please wait while we load your information from QuoteMedia.